FONTUP® AT THE ANNUAL CONGRESS OF THE SPANISH SOCIETY OF NEUROLOGY

Engaging physicians in the role of FontUp® and early intervention strategies in cognitive health

Neurological disorders, particularly those linked to cognitive decline, continue to pose a growing public health challenge. As interest in early-intervention strategies rises, evidence-based nutritional solutions are gaining attention among clinicians and researchers.

In this context, Laboratoires Grand Fontaine participated in the Annual Congress of the Spanish Society of Neurology (SEN), presenting FontUp^® as a scientifically supported nutritional option designed to complement emerging approaches in preventive cognitive care.

During the congress, we shared insights related to EGCG (Epigallocatequin-3-gallate), a polyphenol found in the green tea that forms the basis of FontUp^®, and its potential role in supporting cognitive function. We also provided clinicians with updated information on the product’s formulation, recommended dosing and practical applications in routine clinical practice.

The scientific foundation presented included key outcomes from the PENSA study, which explored the combination of lifestyle-based interventions and FontUp^® in individuals with subjective cognitive decline and increased genetic risk of Alzheimer’s Disease.

Key Messages highlighted at SEN included:

• FontUp^® improves cognitive performance and maintains its beneficial effects over time.
• FontUp^® reduces the risk of developing dementia.
• FontUp^®’s standardized formulation is safe and well-tolerated.
• Preventive, multidomain strategies are becoming increasingly relevant in neurology, and FontUp^® aligns with this evolving paradigm.

Our participation in the SEN Congress reinforces Laboratoires Grand Fontaine’s commitment to advancing evidence-based nutritional solutions that support clinicians in addressing cognitive decline from its earlies stages.